Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANTIRIN vs Nasic vs placebo in allergic rhinitis
2006-000435-99Phase 3Completed
- Sponsor
- Zentiva
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of xylometazoline + dexpanthenol in allergic rhinitis (AR) (3 arms), sponsored by Zentiva. Primary endpoint: Change in Total Nasal Symptom Score (TNSS) from baseline to Day 4. Started Apr 2006; status: completed.
02
Drugs
xylometazoline + dexpanthenol
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on 2006-000435-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000435-99.